What Is Non-Hodgkin's Lymphoma?
Title: What Is Non-Hodgkin's Lymphoma?Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 10/6/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 6, 2021 Category: Cancer & Oncology Source Type: news

Hospital, outpatient visits main drivers of costs for non-Hodgkin's lymphoma survivors in France
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

Sharing Mayo Clinic: Diversity in bone marrow transplantation is gift of life for their mom
Only 20% of minorities are able to find a match when they require a transplant. But for one African American mom of five, finding that match meant the gift of life. _______________________________ Family is everything to Felicia Curtis. Family is the reason the mother of five from Gainesville, Florida, knew she had to fight when she was diagnosed with non-Hodgkin's lymphoma in 2017. She was 20 weeks pregnant with her youngest child. Over the next several months,… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 26, 2021 Category: Databases & Libraries Source Type: news

Lung Cancer, Non-Hodgkin Lymphoma Biggest Contributors to Life-Years Lost to Cancer in Transplant Patients Lung Cancer, Non-Hodgkin Lymphoma Biggest Contributors to Life-Years Lost to Cancer in Transplant Patients
Transplant recipients have a shortened lifespan after developing cancer, especially those who develop lung cancer and non-Hodgkin lymphoma, according to a new analysis.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 22, 2021 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

FDA Approval for Zanubrutinib in Waldenstr öm’s Macroglobulinemia FDA Approval for Zanubrutinib in Waldenstr öm’s Macroglobulinemia
The US Food and Drug Administration has approved zanubrutinib for use in the treatment of adult patients with a rare form of non-Hodgkin lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Media News - August 9, 2021 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Investor Update - August 9, 2021 Category: Pharmaceuticals Source Type: news

Researchers discover a novel class of drugs that may help treat a deadly type of lymphoma
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A new class of drugs that inhibits a 'master switch' involved in the vast majority of cases of mantle cell lymphoma (MCL), a fatal subtype of non-Hodgkin's lymphoma, has been discovered by researchers at Mount Sinai. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 22, 2021 Category: Biology Source Type: news

Prolonged COVID-19 Common Among Patients With Lymphoma Prolonged COVID-19 Common Among Patients With Lymphoma
Approximately a third of patients with B-cell non-Hodgkin lymphoma require hospitalization for COVID-19 beyond 30 days. Older age and anti-CD20 therapy are key risk factors.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 14, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 8, 2021 Category: Pharmaceuticals Authors: Sonia Waraich Source Type: news

Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy® (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) will be p resented at the 2021 ASCO Annual Meeting from 4-8 June 2021. (Source: Roche Media News)
Source: Roche Media News - June 4, 2021 Category: Pharmaceuticals Source Type: news

Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy® (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) will be p resented at the 2021 ASCO Annual Meeting from 4-8 June 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - June 4, 2021 Category: Pharmaceuticals Source Type: news

Bayer loses appeal of $25 million verdict, making more Roundup lawsuits likely
Bayer lost its appeal of a $25 million ruling that Roundup caused a California man's non-Hodgkins lymphoma. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 17, 2021 Category: Pharmaceuticals Authors: Greg Edwards Source Type: news

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Media News - May 11, 2021 Category: Pharmaceuticals Source Type: news

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Investor Update - May 11, 2021 Category: Pharmaceuticals Source Type: news

Combo Provides'Broad Benefit' Across NHL Subtypes Combo Provides'Broad Benefit' Across NHL Subtypes
The combination of copanlisib + rituximab led to a reduction in the risk for disease progression/death when compared with rituximab + placebo in patients with relapsed, indolent non-Hodgkin lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
TUESDAY, April 13, 2021 -- Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Mayo Clinic Minute: Understanding, treating lymphoma
Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The main two subtypes are Hodgkin lymphoma and non-Hodgkin lymphoma. Because of breakthrough research, this once fatal diagnosis has been transformed into a curable condition. In this Mayo Clinic Minute, Dr. Stephen Ansell, a Mayo Clinic hematologist, discusses the [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 30, 2021 Category: Databases & Libraries Source Type: news

Cancer symptoms: Painless swellings may be a sign of non-Hodgkin lymphoma
CANCER will affect one in two of us, meaning 50 percent of the British population will get the deadly disease in their lifetime. What are the early warning signs of non-Hodgkin lymphoma? (Source: Daily Express - Health)
Source: Daily Express - Health - March 24, 2021 Category: Consumer Health News Source Type: news

What Is the Survival Rate for NonHodgkin Lymphoma
What Is the Survival Rate for Non-Hodgkin Lymphoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 24, 2021 Category: General Medicine Source Type: news

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, XpressCF+, multiple myeloma, non-Hodgkin lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news

Penn-developed CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
(University of Pennsylvania School of Medicine) A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah ™ , researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2021 Category: Cancer & Oncology Source Type: news

First Data for CAR T-cell Therapy in Follicular Lymphoma First Data for CAR T-cell Therapy in Follicular Lymphoma
The ZUMA-5 results show impressive responses for patients with refractory/relapsed indolent non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL Steroids Increase Infection Risk With CAR T-Cell Therapy in NHL
Steroids and multiple prior treatments markedly increase the risk of infection following CAR T-cell therapy in patients with high-grade B-cell non-Hodgkin's lymphoma, UK clinicians have found.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL
WEDNESDAY, Dec. 9, 2020 -- Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, is promising for the treatment of relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 9, 2020 Category: Pharmaceuticals Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news

CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma
(Dana-Farber Cancer Institute) A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2020 Category: International Medicine & Public Health Source Type: news

Hodgkin's vs. Non-Hodgkin's Lymphoma
Title: Hodgkin's vs. Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 1/31/2007 12:00:00 AMLast Editorial Review: 11/10/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 10, 2020 Category: Cancer & Oncology Source Type: news

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to de...
Source: Roche Media News - November 5, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to de...
Source: Roche Investor Update - November 5, 2020 Category: Pharmaceuticals Source Type: news

14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news

Many Non-Hodgkin's Lymphoma patients can skip radiation, collaborative study finds
(University of Arizona Health Sciences) Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 6, 2020 Category: Cancer & Oncology Source Type: news

FDA grants Fast Track designation to Calibr's 'switchable' CAR-T cell cancer therapy
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news

Non-Hodgkin's Lymphoma
Title: Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/31/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 31, 2020 Category: Cancer & Oncology Source Type: news

Mayo Clinic Q and A: New blood cancer treatment options with chimeric antigen receptor-T cell therapy
Dear Mayo Clinic: My brother was diagnosed with non-Hodgkin lymphoma a few years ago and has had several recurrences. I was reading about something called chimeric antigen receptor-T cell therapy (CAR-T cell therapy) and was wondering how it works and if he might be a candidate for it? Answer: CAR-T cell therapy is a relatively new treatment that [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 29, 2020 Category: Databases & Libraries Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

Judge Puts Cloud Over Settlement of Roundup Cancer Claims
An agreement for the weedkiller ’s maker to pay more than $10 billion to end litigation may not get court approval. (Source: NYT Health)
Source: NYT Health - July 7, 2020 Category: Consumer Health News Authors: Patricia Cohen Tags: Hazardous and Toxic Substances Suits and Litigation (Civil) Defoliants and Herbicides Non-Hodgkin ' s Lymphoma Bayer AG Monsanto Company Chhabria, Vince Girdhari Feinberg, Kenneth R Roundup Source Type: news

Highlights in Non-Hodgkin Lymphoma From ASCO 2020 Highlights in Non-Hodgkin Lymphoma From ASCO 2020
Highlights in non-Hodgkin lymphoma from the ASCO 2020 virtual annual meeting include new data on CAR T cells in relapsed/refractory NHL, and Bcl-2 inhibition and chemoimmunotherapy in Richter syndrome.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Blood cancer symptoms: Swelling in this part of the body could be a warning sign
BLOOD CANCER - there are three main types: leukaemia, lymphoma and myeloma. Those with non-Hodgkin lymphoma may experience swelling, but where in the body? (Source: Daily Express - Health)
Source: Daily Express - Health - June 18, 2020 Category: Consumer Health News Source Type: news

Roche presents updated data on novel CD20xCD3 bispecific cancer immunotherapy glofitamab in people with heavily pre-treated non-Hodgkin lymphomas
Basel, 12 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data on one of its investigational CD20xCD3 T-cell engaging bispecific antibodies, glofitamab (formerly known as CD20-TCB), in people with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). Updated results from the phase I dose-escalation NP30179 study [NCT03075696] of glofitamab, administered via intravenous infusion for a fixed-duration of up to 12 21-day cycles, showed durable complete responses (CRs) in heavily pre-treated patients who had received a median of three prior lines of therapy. These data feature in an oral presentation (...
Source: Roche Investor Update - June 12, 2020 Category: Pharmaceuticals Source Type: news

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings
The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Caron A. Jacobson, MD Source Type: news

Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

A new immunotherapeutic agent for children and adolescents with advanced lymphoma
(Comprehensive Cancer Centre Gustave Roussy) The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine. It establishes a new standard treatment with an improved cure rate for children with advanced non-Hodgkin lymphoma, mainly Burkitt lymphoma. It supports the value of an immunotherapeutic agent, which was authorised in March 2020 by the European Commission for the treatment of a rare childhood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2020 Category: Cancer & Oncology Source Type: news

Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL
Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

A new therapeutic target turns the immune system against lymphoma
(Ecole Polytechnique F é d é rale de Lausanne) EPFL scientists have identified a key mechanism that tumor cells use to take advantage of and avoid detection from the immune system. Targeting this mechanism offers a new therapeutic strategy for cancers like Non-Hodgkin lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2020 Category: Cancer & Oncology Source Type: news

NFCR-backed technology receives FDA's assent for lymphoma clinical trials
(National Foundation for Cancer Research) National Foundation for Cancer Research-backed drug and drug delivery technology receives assent from US Food and Drug Administration for T-cell non-Hodgkin's lymphoma clinical trials. The milestone represents another example of promising translational cancer research supported by the organization and its donors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2020 Category: Cancer & Oncology Source Type: news